The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†

Glen Lutchman; Apurva A. Modi; David E. Kleiner; Kittichai Promrat; Theo Heller

doi:10.1002/hep.21661

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†

Glen Lutchman, Apurva A. Modi, David E. Kleiner, Kittichai Promrat, Theo Heller, Marc G. Ghany, Brian B. Borg, Rohit Loomba, Tiebing Liang, Ahalya Premkumar, Jay H. Hoofnagle

Lippincott Williams & Wilkins (2007) • Volume 46, Issue 2, Pages 424-429

PDF Available

Abstract

These findings suggest that long-term therapy with pioglitazone may be necessary to maintain improvements in disease activity in patients with NASH, although weight gain during treatment may ultimately limit its beneficial effects.

Quick Actions

Read Full Paper

Publication Info

DOI

10.1002/hep.21661

Language

English

Topic

Liver Disease Diagnosis and Treatment

Keywords

Pioglitazone, Nonalcoholic steatohepatitis, Medicine, Internal medicine, Steatohepatitis, Gastroenterology, Nonalcoholic fatty liver disease, Diabetes mellitus, Fatty liver, Endocrinology, Type 2 diabetes

Published

June 9, 2007

Citations

238 citations

FWCI

18.20

External Resources

DOI Link OpenAlex

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†

Abstract

Quick Actions

Publication Info

External Resources

Suggested Papers

Segment anything in medical images

Enhancing the Valorization of Spent Pleurotus Substrate Through Anaerobic Digestion by Extracted Enzymes

Concise Review: Mesenchymal Stem Cells Derived from Human Pluripotent Cells, an Unlimited and Quality-Controllable Source for Therapeutic Applications

Suggested Papers

Suggested Papers

Segment anything in medical images

Enhancing the Valorization of Spent Pleurotus Substrate Through Anaerobic Digestion by Extracted Enzymes

Concise Review: Mesenchymal Stem Cells Derived from Human Pluripotent Cells, an Unlimited and Quality-Controllable Source for Therapeutic Applications